Cancer drugs funding

NICE sees role for Cancer Drugs Fund but on a different basis, RPS conference hears

The National Institute for Health and Care Excellence (NICE) sees a role for the Cancer Drugs Fund, but it needs to be on a different footing, according to NICE’s programme director of technology appraisals.…

Cancer Drugs Fund needs overhaul, NAO investigation finds

The Cancer Drugs Fund is unsustainable in its current form because of overspending and a lack of evidence on the results it yields, according to a report from the National Audit Office.…

Encouraging pharmaceutical innovation must come first

The ‘de-listing’ of certain treatments from the NHS Cancer Drugs Fund was inevitable with budgets becoming tighter but innovation in drug development must not suffer.…

NHS England cuts treatments from Cancer Drugs Fund

After a second assessment of the Cancer Drugs Fund, NHS England has further reduced the list by 17 drugs for 23 different indications.…

Clinical Pharmacist’s monthly news round-up: the top 10 in the past month

What has been happening in the world of pharmacy? Here’s our pick of must-read news from the past month.…

Proposal to involve NICE in approval process for Cancer Drugs Fund

The evaluation of drugs currently funded under the Cancer Drugs Fund (CDF) could be passed over to National Institute for Health and Care Excellence (NICE) under proposals drawn up by NHS England.…

Global spending on cancer drugs tops US$100bn

Spending on cancer drugs now tops US$100bn globally, a 10.3% rise over the past 12 months, with targeted therapies making up 48% of the total spend.…

UK political parties discuss healthcare and pharmacy issues ahead of general election

Ahead of the UK public going to the polls on 7 May in the 2015 general election, the three largest political parties in Westminster respond to questions on the big issues in healthcare and pharmacy.…

Appraisal processes prevent patients from accessing new anti-cancers, report claims

A report says countries that use a QALY formula to assess cost-effectiveness have less access to new cancer drugs compared with countries that use an alternative system.…

Cancer Drugs Fund has undermined NICE, its chair admits

The Cancer Drugs Fund has undermined the National Institute for Health and Care Excellence and has provided a “get out of jail card” for pharmaceutical companies, its chair says.…